Hamlet BioPharma (HAMLET) Investor Update summary

Tuberculosis project update

• Tuberculosis remains a major global health issue, with 10 million new cases and 1.5 million deaths annually, including significant impact on children and women.

• Multidrug-resistant TB is a growing problem, with new treatments like Baypal recently introduced, but resistance is already emerging.

• Novel peptides derived from fungi, such as plectosin and NZX, show strong efficacy against both drug-susceptible and multidrug-resistant TB in preclinical studies.

• These peptides demonstrate long-lasting effects, broad-spectrum activity, and promising results in animal models, comparable to standard treatments.

• Clinical evaluation is being prepared, with phase I trials potentially starting within a year, pending production and toxicity studies.

Communication, partnerships, and commercialization

• Results are being disseminated through high-impact journals, conferences, and direct engagement with regulatory agencies.

• Ongoing discussions with organizations like TB Alliance aim to support clinical trial progression.

• Commercial production partners are being engaged to scale up manufacturing for clinical evaluation.

• A broad network of contacts is leveraged for market introduction, with plans to accelerate once formal publications are released.

Patent and collaboration structure

• Recent BAMLET patents are held by LinAnna, with development funded independently from Hamlet Biopharma.

• Hamlet Biopharma holds older BAMLET patents, now licensed to LinAnna, consolidating the portfolio and ensuring a 25% royalty for Hamlet on any BAMLET income.

• The collaboration is described as symbiotic, with Hamlet focusing on drug development and commercialization, and LinAnna on research and technology advancement.

• The structure allows for efficient drug development at significantly lower cost compared to industry norms, benefiting investors.